Targeting cancer-initiating cells with oncolytic viruses

Molecular Therapy

Volumn 17, Issue 10, 2009, Pages 1677-1682

  Cripe, Timothy P ^a   Wang, Pin Yi ^a   Marcato, Paola ^b   Mahller, Yonatan Y ^a   Lee, Patrick W K ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; G 207; NESTIN; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES SIMPLEX VIRUS 2; ONCOLYTIC HERPES VIRUS; ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC REOVIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; R 3616; RQNESTIN 34.5; UNCLASSIFIED DRUG; VALPROIC ACID; VIROTHERAPY AGENT;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER RELAPSE; CANCER STEM CELL; CARCINOGENESIS; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; HERPES SIMPLEX VIRUS; HUMAN; MYXOMA VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; REOVIRUS; REVIEW; SINGLE DRUG DOSE; TARGET CELL DESTRUCTION; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY; VIRUS MUTANT;

ANIMALS; HUMANS; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 70349869660     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.193     Document Type: Review

References (81)

1. Jordan, CT (2009). Cancer stem cells: Controversial or just misunderstood? Cell Stem Cell 4: 203-205.
2. Islam, MO, Kanemura, Y, Tajria, J, Mori, H, Kobayashi, S, Hara, M et al. (2005). Functional expression of ABCG2 transporter in human neural stem/progenitor cells. Neurosci Res 52: 75-82.
3. Donnenberg, VS and Donnenberg, AD (2005). Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. J Clin Pharmacol 45: 872-877.
4. Dingli, D and Michor, F (2006). Successful therapy must eradicate cancer stem cells. Stem Cells 24: 2603-2610.
5. Liu, TC and Kirn, D (2008). Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 15: 877-884.
6. Power, AT and Bell, JC (2007). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 15: 660-665.
7. Coukos, G, Makrigiannakis, A, Kang, EH, Rubin, SC, Albelda, SM and Molnar-Kimber, KL (2000). Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 6: 3342-3353.
8. Mahller, YY, Williams, JP, Baird, WH, Mitton, B, Grossheim, J, Saeki, Y et al. (2009). Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 4: E4235.
9. Singh, SK, Clarke, ID, Terasaki, M, Bonn, VE, Hawkins, C, Squire, J et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
10. Singh, SK, Hawkins, C, Clarke, ID, Squire, JA, Bayani, J, Hide, T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396-401.
11. Reynolds, BA and Weiss, S (1992). Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255: 1707-1710.
12. Lee, J, Kotliarova, S, Kotliarov, Y, Li, A, Su, Q, Donin, NM et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403.
13. Bolovan, CA, Sawtell, NM and Thompson, RL (1994). ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J Virol 68: 48-55.
14. He, B, Gross, M and Roizman, B (1997). The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 94: 843-848.
15. MacKie, RM, Stewart, B and Brown, SM (2001). Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357 525-526.
16. Harrow, S, Papanastassiou, V, Harland, J, Mabbs, R, Petty, R, Fraser, M et al. (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Ther 11: 1648-1658.
17. Papanastassiou, V, Rampling, R, Fraser, M, Petty, R, Hadley, D, Nicoll, J et al. (2002). The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study. Gene Ther 9: 398-406.
18. Hu, JC, Coffin, RS, Davis, CJ, Graham, NJ, Groves, N, Guest, PJ et al. (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12: 6737-6747.
19. Mace, AT, Ganly, I, Soutar, DS and Brown, SM (2008). Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck 30: 1045-1051.
20. Markert, JM, Medlock, MD, Rabkin, SD, Gillespie, GY, Todo, T, Hunter, WD et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther 7: 867-874.
21. Markert, JM, Liechty, PG, Wang, W, Gaston, S, Braz, E, Karrasch, M et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
22. Kambara, H, Okano, H, Chiocca, EA and Saeki, Y (2005). An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832-2839.
23. Otsuki, A, Patel, A, Kasai, K, Suzuki, M, Kurozumi, K, Chiocca, EA et al. (2008). Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 16: 1546-1555.
24. Maris, JM, Hogarty, MD, Bagatell, R and Cohn, SL (2007). Neuroblastoma. Lancet 369: 2106-2120.
25. Hansford, LM, McKee, AE, Zhang, L, George, RE, Gerstle, JT, Thorner, PS et al. (2007). Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 67: 11234-11243.
26. Wakimoto, H, Kesari, S, Farrell, CJ, Curry, WT, Zaupa, C, Aghi, M et al. (2009). Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69: 3472-3481.
27. Todo, T, Martuza, RL, Rabkin, SD and Johnson, PA (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98: 6396-6401.
28. Friedman, GK, Langford, CP, Coleman, JM, Cassady, KA, Parker, JN, Markert, JM et al. (2009). Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. J Neurooncol (epub ahead of print)
29. Bao, S, Wu, Q, McLendon, RE, Hao, Y, Shi, Q, Hjelmeland, AB et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
30. Aghi, M, Rabkin, S and Martuza, RL (2006). Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 98: 38-50.
31. Whyte, P, Buchkovich, KJ, Horowitz, JM, Friend, SH, Raybuck, M, Weinberg, RA et al. (1988). Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334: 124-129.
32. Fueyo, J, Gomez-Manzano, C, Alemany, R, Lee, PS, McDonnell, TJ, Mitlianga, P et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2-12.
33. Heise, C, Hermiston, T, Johnson, L, Brooks, G, Sampson-Johannes, A, Williams, A et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6: 1134-1139.
34. Tomko, RP, Xu, R and Philipson, L (1997). HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94: 3352-3356.
35. Ribacka, C and Hemminki, A (2008). Virotherapy as an approach against cancer stem cells. Curr Gene Ther 8: 88-96.
36. Kanerva, A, Zinn, KR, Chaudhuri, TR, Lam, JT, Suzuki, K, Uil, TG et al. (2003). Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 8 449-458.
37. Ranki, T, Kanerva, A, Ristimäki, A, Hakkarainen, T, Särkioja, M, Kangasniemi, L et al. (2007). A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther 14: 58-67.
38. -/low cells. Mol Ther 15: 2088-2093.
39. Al-Hajj, M, Wicha, MS, Benito-Hernandez, A, Morrison, SJ and Clarke, MF (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
40. Ponti, D, Costa, A, Zaffaroni, N, Pratesi, G, Petrangolini, G, Coradini, D et al. (2005). Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511.
41. -/low breast cancer cells. Cancer Res 68: 5533-5539.
42. Jiang, H, Gomez-Manzano, C, Aoki, H, Alonso, MM, Kondo, S, McCormick, F et al. (2007). Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: Role of autophagic cell death. J Natl Cancer Inst 99: 1410-1414.
43. Skog, J, Edlund, K, Bergenheim, AT and Wadell, G (2007). Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells. Mol Ther 15: 2140-2145.
44. Stanford, MM and McFadden, G (2007). Myxoma virus and oncolytic virotherapy: A new biologic weapon in the war against cancer. Expert Opin Biol Ther 7: 1415-1425.
45. Wang, G, Barrett, JW, Stanford, M, Werden, SJ, Johnston, JB, Gao, X et al. (2006). Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA 103: 4640-4645.
46. Redding, N, Zhou, H-Y, Lun, X, Senger, D, Forsyth, P, Robbins, S, et al. (2009). The utility of oncolytic viruses against neuroblastoma. In The 5th International Meeting on Replicating Oncolytic Virus Therapeutics, Banff, Canada.
47. Sartelet, H, Oligny, LL and Vassal, G (2008). AKT pathway in neuroblastoma and its therapeutic implication. Expert Rev Anticancer Ther 8: 757-769.
48. Alain, T, Hirasawa, K, Pon, KJ, Nishikawa, SG, Urbanski, SJ, Auer, Y et al. (2002). Reovirus therapy of lymphoid malignancies. Blood 100: 4146-4153.
49. Coffey, MC, Strong, JE, Forsyth, PA and Lee, PW (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334.
50. Norman, KL, Coffey, MC, Hirasawa, K, Demetrick, DJ, Nishikawa, SG, DiFrancesco, LM et al. (2002). Reovirus oncolysis of human breast cancer. Hum Gene Ther 13: 641-652.
51. Smakman, N, van den Wollenberg, DJ, Borel Rinkes, IH, Hoeben, RC and Kranenburg, O (2005). Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J Virol 79: 14981-14985.
52. Wilcox, ME, Yang, W, Senger, D, Rewcastle, NB, Morris, DG, Brasher, PM et al. (2001). Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93: 903-912.
53. Yang, WQ, Senger, DL, Lun, XQ, Muzik, H, Shi, ZQ, Dyck, RH et al. (2004). Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther 11: 1579-1589.
54. Yap, TA, Brunetto, A, Pandha, H, Harrington, K and Debono, JS (2008). Reovirus therapy in cancer: Has the orphan virus found a home? Expert Opin Investig Drugs 17: 1925-1935.
55. Marcato, P, Dean, CA, Giacomantonio, CA and Lee, PW (2009). Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther 17: 972-979.
56. Ginestier, C, Hur, MH, Charafe-Jauffret, E, Monville, F, Dutcher, J, Brown, M et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567.
57. Wulf, GG, Wang, RY, Kuehnle, I, Weidner, D, Marini, F, Brenner, MK et al. (2001). A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98: 1166-1173.
58. Todaro, M, Alea, MP, Di Stefano, AB, Cammareri, P, Vermeulen, L, Iovino, F et al. (2007). Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402.
59. + cancer stem cells in glioblastoma. Mol Cancer 5: 67.
60. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758.
61. Hermann, PC, Huber, SL, Herrler, T, Aicher, A, Ellwart, JW, Guba, M et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
62. Strong, JE, Coffey, MC, Tang, D, Sabinin, P and Lee, PW (1998). The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362.
63. Bos, JL (1989). ras oncogenes in human cancer: A review. Cancer Res 49: 4682-4689.
64. Malumbres, M and Pellicer, A (1998). RAS pathways to cell cycle control and cell transformation. Front Biosci 3: D887-d912.
65. Marcato, P, Shmulevitz, M, Pan, D, Stoltz, D and Lee, PW (2007). Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 15: 1522-1530.
66. Golden, JW, Linke, J, Schmechel, S, Thoemke, K and Schiff, LA (2002). Addition of exogenous protease facilitates reovirus infection in many restrictive cells. J Virol 76: 7430-7443.
67. Alain, T, Kim, TS, Lun, X, Liacini, A, Schiff, LA, Senger, DL et al. (2007). Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol Ther 15: 1512-1521.
68. Smakman, N, van den Wollenberg, DJ, Elias, SG, Sasazuki, T, Shirasawa, S, Hoeben, RC et al. (2006). KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 66: 5403-5408.
69. Clarke, P, Meintzer, SM, Wang, Y, Moffitt, LA, Richardson-Burns, SM, Johnson, GL et al. (2004). JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells. J Virol 78: 13132-13138.
70. Connolly, JL, Rodgers, SE, Clarke, P, Ballard, DW, Kerr, LD, Tyler, KL et al. (2000). Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB. J Virol 74: 2981-2989.
71. Finco, TS, Westwick, JK, Norris, JL, Beg, AA, Der, CJ and Baldwin, AS (1997). Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 272: 24113-24116.
72. Pruitt, K, Pruitt, WM, Bilter, GK, Westwick, JK and Der, CJ (2002). Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation. J Biol Chem 277 31808-31817.
73. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6 821-825.
74. Balachandran, S, Porosnicu, M and Barber, GN (2001). Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 75: 3474-3479.
75. Lichty, BD, Power, AT, Stojdl, DF and Bell, JC (2004). Vesicular stomatitis virus: Re-inventing the bullet. Trends Mol Med 10 210-216.
76. Fernandez, M, Porosnicu, M, Markovic, D and Barber, GN (2002). Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 76: 895-904.
77. Bergman, I, Whitaker-Dowling, P, Gao, Y, Griffin, JA and Watkins, SC (2003). Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/ neu overexpressing breast cancer cells. Virology 316: 337-347.
78. Korkaya, H, Paulson, A, Iovino, F and Wicha, MS (2008). HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27: 6120-6130.
79. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
80. Lun, X, Senger, DL, Alain, T, Oprea, A, Parato, K, Stojdl, D et al. (2006). Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst 98: 1546-1557.
81. Sinkovics, JG and Horvath, JC (2008). Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) 56 Suppl 1: 3s-59s.